FAS Wealth Partners’s Tenax Therapeutics TENX Stock Holding History

FAS Wealth Partners’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-36	Closed	-$10K	–	434
2022 Q3	$10K	Hold	36	–	–	﹤0.01%	371
2022 Q2	$17K	Hold	36	–	–	﹤0.01%	365
2022 Q1	$47K	Hold	36	–	–	﹤0.01%	328
2021 Q4	$61K	Hold	36	–	–	0.01%	332
2021 Q3	$103K	Hold	36	–	–	0.01%	310
2021 Q2	$127K	Hold	36	–	–	0.01%	291
2021 Q1	$111K	Hold	36	–	–	0.01%	276
2020 Q4	$108K	Sell	36 -1	-3%	-$1.84K	0.01%	267
2020 Q3	$90K	Hold	37	–	–	0.01%	256
2020 Q2	$53K	Hold	37	–	–	0.01%	258
2020 Q1	$33K	Hold	37	–	–	0.01%	252
2019 Q4	$83K	Hold	37	–	–	0.01%	219
2019 Q3	$70K	Hold	37	–	–	0.01%	191
2019 Q2	$81K	Hold	37	–	–	0.02%	191
2019 Q1	$118K	Hold	37	–	–	0.02%	188
2018 Q4	$71K	Hold	37	–	–	0.02%	187
2018 Q3	$308K	Hold	37	–	–	0.07%	151
2018 Q2	$370K	Hold	37	–	–	0.1%	133
2018 Q1	$320K	Sell	37 -3	-8%	-$34.5K	0.09%	137
2017 Q4	$633K	Hold	40	–	–	0.17%	88
2017 Q3	$466K	Buy	+40	New	+$594K	0.13%	113

Other funds holding TENX

Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FAS Wealth Partners's TENX Position: Q4 2022 in Review

FAS Wealth Partners sold out of Tenax Therapeutics (TENX) in Q4 2022, closing a stake of 36 shares — an estimated $10K sold.

FAS Wealth Partners first reported a position in TENX in Q3 2017 and held it in 21 quarters. The position peaked at $633K in Q4 2017. 14 funds tracked by Wall St. Rank hold TENX as of Q4 2022.

FAS Wealth Partners reported no remaining Tenax Therapeutics position as of Q4 2022 after selling out during the quarter.
FAS Wealth Partners sold 36 Tenax Therapeutics shares in Q4 2022, an estimated $10K.
FAS Wealth Partners first reported a position in Tenax Therapeutics in Q3 2017 and held it in 21 quarters.
FAS Wealth Partners's Tenax Therapeutics position peaked at $633K in Q4 2017.
14 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2022.

Based on FAS Wealth Partners's 13F filing for Q4 2022, filed 1 Feb 2023.